Business context and reporting period
The supplied filing is Theravance, Inc.’s Form 10-K for the fiscal year ended December 31, 2014—not an Innoviva, Inc. filing. Confirm issuer identity before relying on this summary. The filing covers the year and includes unaudited fourth-quarter results.
After its June 2014 spin-off of Theravance Biopharma, Theravance became a small royalty-management company focused mainly on respiratory products partnered with GSK, including RELVAR/BREO ELLIPTA and ANORO ELLIPTA. The former research and development business is reported as discontinued operations. Theravance had 10 employees at year-end.
Financial performance and position
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Net revenue from continuing operations | $8.4 million | $4.5 million |
| Operating expenses | $42.4 million | $33.3 million |
| Operating loss | $33.9 million | $28.8 million |
| Loss from continuing operations | $73.5 million | $30.6 million |
| Net loss, including discontinued operations | $168.5 million | $170.7 million |
| Operating cash flow | $(130.7) million | $(129.6) million |
FY 2014 royalty revenue, net of amortization of milestone fees paid to GSK, was $7.4 million; gross royalties were $18.4 million. The filing reports fourth-quarter revenue of $7.3 million, operating expenses of $7.2 million, and continuing-operations loss of $15.9 million. Gross margin is not separately reported.
At December 31, 2014, cash, cash equivalents and marketable securities totaled $283.4 million, versus $520.5 million a year earlier; working capital was $238.4 million. Total long-term debt was $725.6 million: $255.1 million of 2.125% convertible notes due 2023 and $470.5 million recorded for 9% non-recourse notes due 2029. The latter are serviced from 40% of specified GSK royalties. Stockholders’ deficit was $223.3 million.
Material changes versus the prior period
- Revenue rose 86% from 2013, principally as royalties began on ANORO and RELVAR/BREO generated a full year of royalties. Revenue comparisons are affected by the spin-off and by the recognition of collaboration revenue in prior periods.
- Continuing-operations loss widened by $42.9 million, mainly due to higher employee-related and stock-based compensation costs and increased interest expense after the 2029 notes issuance.
- Cash and marketable securities fell by $237.1 million. Major uses included the $393.0 million contribution to Theravance Biopharma, $130.7 million of operating cash use, $135.0 million of 2014 milestone payments to GSK and $57.0 million of dividends; financing proceeds partly offset these uses.
- GSK product sales grew sequentially in Q4: RELVAR/BREO sales were $62.2 million, up from $25.6 million in Q3; ANORO sales were $17.4 million, up from $1.8 million. These are GSK sales, not Theravance revenue.
Outlook, risks and unusual items
- Management expected 2015 R&D and G&A expenses to decrease following the spin-off, and said available cash and expected royalties should fund operations for at least 12 months under current plans. No specific revenue or earnings guidance was provided.
- The board declared a $0.25-per-share first-quarter 2015 dividend, approximately $29.2 million in total. Future capital returns are discretionary and depend on financial and contractual factors.
- Commercialization remains dependent on GSK; management disclosed that product launches and sales to date were below expectations, citing U.S. pricing and reimbursement access. Competition, coverage, pricing, regulatory developments and clinical outcomes could materially affect royalties.
- The SEC staff was discussing Theravance’s accounting for historical GSK upfront and milestone receipts and milestone fees paid in 2013–2014. The company said it believed its accounting was appropriate, but acknowledged a possible restatement if the SEC disagreed.
- Unusual items include the June spin-off, $220.0 million of cumulative GSK milestone fees paid by year-end, $36.9 million of interest expense, and a $3.8 million impairment loss on Theravance Biopharma shares. The 2029 notes add interest shortfalls to principal under specified conditions through May 2016.
- Other material exposures include potential limits on use of tax attributes, reliance on a small team and transitional services, the lease guarantee for facilities assigned to Theravance Biopharma, and dependence on GSK-related royalties to service debt.
Investor verification priorities
- Confirm issuer and ticker: the supplied document identifies Theravance, Inc. (THRX), not Innoviva, Inc.
- Track the SEC accounting discussions and any subsequent restatement, filing or auditor developments.
- Check subsequent GSK sales, net pricing, reimbursement access and resulting royalties, including the impact of 40% royalty diversion to the 2029 notes.
- Review debt principal, interest accruals, conversion or put rights, and the cash available after debt service and dividends.
- Assess whether the stated 12-month liquidity outlook and planned expense reductions were achieved, and whether dividends continued.